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Immune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune
regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be
a promising strategy for cancer immunotherapy. In this study, we examined the eﬀectiveness of 4-1BBL-expressing tumor cell
vaccine in combination with CTLA-4 blockade on rejection of murine prostate cancer RM-1. We found that the combination
of both a vaccine consisting of 4-1BBL-expressing RM-1 cells and CTLA-4 blockade resulted in regression of RM-1 tumors and a
signiﬁcantincreaseinsurvivalofthetumourcellrecipients,comparedtothatofeithertreatmentalone.Thecombinedvaccination
resulted in higher CTL against RM-1 cells and increased secretion of IFN-γ,T N F - α, and IL-2 in the mix-cultured supernatant.
These results suggest that combining activation of 4-1BB and blockade of CTLA-4 may oﬀer a new strategy for prostate cancer
immunotherapy.
1.Introduction
Prostate cancer (PCa) is the most frequently diagnosed
cancer in old men and also the second leading cause of
male cancer death in the western countries [1]. In addition,
the incidence and mortality of carcinoma of prostate are
increasing in China. Although radical prostatectomy and
radiation therapy remain the optimal choice for localized
stage of PCa, there is no eﬀective treatment for patients
whodeveloprecurrencesordevelopintohormone-resistance
prostate cancer (HRPC) or those who have metastatic
disease at the time of diagnosis. Therefore, new therapeutic
approaches to control or even eliminate residual tumor
cells are deﬁnitely needed, providing an opportunity for
immunotherapy [2].
It is well known that T-cell-mediated immune response
plays a great important role in antitumor immunity. An
eﬀective T-cell response can attack tumor cells only after T
cell receives two key signals from the peptide/MHC com-
plexes and costimulatory signals (including B7-1/2, 4-1BBL,
and CD40). Without costimulation, T-cells will undergo
apoptosis or become anergic [3–5]. The fact that tumor cells
are found to have low expression of costimulatory molecule
may explain how tumor cells evade the immune surveillance.
Consistent with this possibility, researchers demonstrated
that conferring 4-1BBL expression to tumors of a variety of
tissueoriginswas,inmanycases,suﬃcienttopromotetumor
rejection by a CD8+ T-cell-dependent mechanism [6, 7].
4-1BBL (CD137L), the counterreceptor for 4-1BB, is
a member of the TNF (ligand) superfamily and serves as
a secondary signal to activated T cells. 4-1BB signaling
can induce cytokine production, expansion, and functional
maturation of T cells, dendritic cells, NK cells, and mono-
cytes [8, 9]. With regard to tumor biology, binding of 4-
1BB has been demonstrated to prevent and even rescue
anergic CD8+ T cells in a number of tolerance-inducing
models [10]. Also, 4-1BBL costimulation can retrieve CD28
expressioninactivatedTcells[11].Asoluble4-1BBLhasalso
beenshowntoovercomeimmunologicalignorance,allowing
immunization with tumor-derived peptide to induce a
protective CTL response [12].
CTLA-4, a close homolog of CD28, is upregulated on
activated T cells and binds B7-1 and B7-2 with considerably
greater avidity than CD28 results in the transduction of2 Clinical and Developmental Immunology
an inhibitory signal and thereby functions as a negative
regulator of T-cell activation in both CD4+ and CD8+
T cells [13]. When CTLA-4/B7 interactions are blocked
by injection of anti-CTLA-4 monoclonal antibody during
cancervaccination,therapeuticT-cellimmunity againsteven
poorly immunogenic tumours such as B16 melanoma can be
eliminated[14].Thiseﬀectispartlymediatedbyanincreased
expansion of antigen-speciﬁc CTL [15, 16]. It has been
reported that blockade of CTLA-4/B7 interactions prevents
induction of peripheral T-cell tolerance upon vaccination
with peptides under tolerogenic conditions, suggesting that
CTLA-4mightbeactivelyinvolvedintheinductionofanergy
[17].
In the present work, we investigated the eﬀect of a
vaccine combined with 4-1BBL-expressing tumor vaccine
and CTLA-4 blockade on the survival of C57BL/6 mice
transplanted subcutaneously with prostate cancer RM-1
cells. We found that 4-1BBL-expressing tumor vaccine in
combinationwithCTLA-4blockadewaseﬀectiveinreducing
tumorincidenceandincreasinginsurvivalofthetumourcell
recipients.
2.MaterialsandMethods
2.1. Animals, Cell Lines, and Antibodies. Female C57BL/6
(H-2 Kb) mice, 6–8 weeks old, were obtained from Shang-
hai SLAC Laboratory Animal Co. Ltd (Shanghai, China).
Animals were maintained at the Central Animal Facility
of Wuhan University according to standard guidelines, and
experiments were conducted according to the guidelines of
theChinaCouncilforAnimalCare.Allmicearekilledbycer-
vical dislocation in the experiment. RM-1, a murine prostate
cancer cell line, was obtained from Chinese Academy of
Sciences (Shanghai, China). All cells were cultured in RPMI-
1640 medium with 10% heat-inactivated FCS, 2mM L-
glutamine, 100U/mL penicillin, and 100μg/mL strepto-
mycin at 37◦C in a humidiﬁed atmosphere containing 5%
CO2. Anti-mouse CTLA-4 (clone 9H10) or hamster IgG
isotype control was obtained from BioXCell; anti-4-1BBL
was purchased from Santa Cruz.
2.2. Stable Transfection of RM-1 Cells with 4-1BBL Plasmid.
The RM-1 cells were transfected with 2μg of pCDNA3.1-
4-1BBL or empty vector by the mediation of 6μLL i p o -
fectamine 2000 (Invitrogen, Carlsbad, CA, USA), according
to the manufacturer’s instructions. After 2 days of culture,
the cells were reseeded into a 10cm dish and cultured for
another 2 days; complete RPMI-1640 medium containing
1000μg/mL G418 (Sigma, St. Louis, MO) was added to the
culture. After 20 days of selection, all nontransfected cells
died, and discrete clones were visible in transfected cells.
These clones were expanded in the presence of 200μg/ml
G418; positive cells expressing 4-1BBL or not were named
RM-1/4-1BBL and RM-1/ pCDNA3.1.
2.3. Western Blot Analysis. To determine 4-1BBL expression,
positivecells(5×106)werelysedandsubjectedtoSDS-P A GE.
Then protein was transferred to a nitrocellulose membrane
(Amersham, USA). The transferred membrane was probed
with polyclonal goat anti-4-1BBL antibody, followed by a
horseradish peroxidase-conjugated anti-goat IgG secondary
antibody (Santa Cruz, CA). Antibodies on membrane were
visualized by chemiluminescence (Pierce, Rockford, IL).
Western blot for β-actin was used as an internal sample.
2.4. Subcutaneous Challenge and Immunization. Mice were
shaved on the back and challenged subcutaneously with 2 ×
105 RM-1 cells in PBS. At the same day or later as indicated,
parentalandtransducedcellswereincubatedwith100μg/mL
mitomycin C (MMC) for 1 hour as cancer vaccine, and
treatment was initiated by injecting 106 cancer vaccine cells
(in PBS) subcutaneously into the left ﬂank and repeated 3
and 6d later. Treatment with 9H10 or control hamster IgG
was started simultaneously or 3d later with similar results.
Antibodiesweredeliveredintraperitoneallyat100mginPBS,
usually followed by two 50mg injections every 3d. Tumor
growth was scored by measuring perpendicular diameters.
Micewerekilledwhenthetumorsdisplayedsevereulceration
or reached a size of 1000mm2.
2.5.GenerationofCTLCultures andCTLAssay. Spleens were
harvested from mice rejecting RM-1 cells and restimulated
in vitro with MMC-treated RM-1 cells, and recombinant
human IL-2 was added to a ﬁnal concentration of 50IU/mL.
After 7d, cells were collected and puriﬁed by Ficoll-
Histopaque (Sigma-Aldrich) gradient centrifugation and
served as eﬀector cells. Target cells (2.5 × 105 per well)
were cocultured with eﬀector cells (5 × 104 per well) at
diﬀerent E:T ratios in 96 round bottom plates. After a 48-
hour incubation at 37◦C, the amount of released lactate
dehydrogenase was determined by using Cell Counting Kit-
8 (Dojindo, Japan) assay according to the manufacturer’s
instructions.Alldeterminationswerecarriedoutintriplicate
and repeated three times. The percentage of speciﬁc cyto-
toxicity was calculated as [target control − (experimental −
eﬀectorcontrol)/target control] ×100%.
2.6. Enzyme-Linked Immunosorbent Assay. 24h after target
cell cocultured with eﬀector cells, the supernatant was
collected and tested for the presence of IFN-γ,T N F - α,a n d
IL-2 by ELISA according to the manufacturer’s instructions
(Pharmingen).
2.7. Statistical Analysis. Data were presented as mean ±
standard deviation. Statistical diﬀerences were considered
to be signiﬁcant at a Pvalue <0.05 as determined by an
ANOVA or Student’s t-test using SPSS13.0. Comparison
among groups in the survival data was made using the log-
rank test.
3. Results
3.1. Establishment of RM-1 Cells Expressing 4-1BBL. RM-
1 cells were transfected with pCDNA3.1 and pCDNA3.1/4-
1BBL, and the G418-resistant cells (RM-1/pCDNA3.1, RM-
1/4-1BBL) were selected. Western blot analysis showed theClinical and Developmental Immunology 3
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Figure 1: Total cell lysates were harvested, and presence of 4-1BBL
protein was detected by anti-4-1BBL pAb. A speciﬁc band was
identiﬁed in positive clone but not in RM-1 cells transfected with
empty vector. β-actin was used as reference.
expression of 4-1BBL in parental and transduced cells,
respectively (Figure 1).
3.2.CTLA-4BlockadeTogetherwith4-1BBL-ExpressingCellu-
lar Vaccines Causes Rejection of RM-1 Tumors. To determine
the eﬀect of 4-1BBL-expressing cellular vaccines combined
with CTLA-4 blockade on tumor growth in vivo, parental
RM-1, RM-1/pCDNA3.1, and pCDNA3.1/4-1BBL cells were
injected into the ﬂank of mice. Tumor growth in mice
injected with pCDNA3.1/4-1BBL cells was slower than that
in mice injected with parental RM-1 or RM-1/pCDNA3.1.
Administration of anti-CTLA-4 antibody 9H10 delayed
growth of RM-1 tumors, but control hamster IgG had
no eﬀect. However, the combination of 4-1BBL-expressing
vaccine and CTLA-4 blockade induced more obvious eﬀec-
tiveness on RM-1 tumor growth than either treatment
alone. 4/5 mice rejected RM-1 tumors after the combinated
treatment (Figure 2).
3.3. CTLA-4 Blockade Together with 4-1BBL-Expressing Cel-
lular Vaccines Increased CTL Activity and Production of
Cytokines. To determine the immune function of 4-1BBL-
expressingcellularvaccinescombinedwithCTLA-4blockade
in vitro, CTL activity of splenocytes from immunized
m i c ew a se v a l u a t e d .A ss h o w ni nFigure 3,C T La c t i v i t yo f
splenocytes from mice immunized with the combination
of 4-1BBL-expressing vaccine and CTLA-4 blockade was
dramatically higher than that from mice treated either alone.
Vaccination with parental RM-1, RM-1/pCDNA3.1, and
control hamster IgG had no eﬀect on CTL activity. Also, the
level of cytokines in supernatant cocultured cells was exam-
ined. The results showed that the levels of cytokines (IFN-γ,
TNF-α, and IL-2) in supernatant from mice vaccinated with
4-1BBL-expressingvaccineandCTLA-4blockadeweremuch
higher than that from mice immunized with either alone
(Figure 4).
3.4. CTLA-4 Blockade Together with 4-1BBL-Expressing Cel-
lular Vaccines Prolonged the Life Span of Mice Rechallenged
Tumors. To determine the immune protection eﬀect of 4-
1BBL-expressing cellular vaccines combined with CTLA-4
blockade, mice were inoculated subcutaneously with lethal
dose of parental RM-1 cells to monitor survival daily. The
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Figure 2: Antitumor immunity in vivo. Mice were challenged
subcutaneously with RM-1 cells (2 × 105 cells/mouse), then 106
tumor vaccine cells (RM-1, RM-1/pCDNA3.1, RM-1/4-1BBL) were
immunized at the same day, with 9H10 or control hamster IgG
intraperitoneally every 3d. The data are expressed as means ± SD
of three replicates (
∗P < 0.05).
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Figure 3: Cytotoxicity assay. Spleens were harvested from mice
rejecting RM-1 cells and restimulated in vitro with MMC-treated
RM-1 cells. 7d later, cells were collected and puriﬁed by Ficoll-
Histopaque gradient centrifugation as eﬀector cells for detecting
speciﬁc cytotoxicity against target cells. The data are expressed as
means ± SD of three replicates (
∗P < 0.05).
survivalrateofmiceimmunizedwithbothCTLA-4blockade
and 4-1BBL-expressing cellular vaccines was signiﬁcantly
higher than that of mice immunized with either alone
(Figure 5).4 Clinical and Developmental Immunology
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Figure 4: Cytokine ELISA. Spleens were harvested from mice
rejecting RM-1 cells and restimulated in vitro with MMC-treated
RM-1 cells. 7d later, cells were collected and puriﬁed by Ficoll-
Histopaque gradient centrifugation as eﬀector cells coculturing
with RM-1 cells. The The supernatant was collected and tested for
the presence of IFN-γ,T N F - α and IL-2 by ELISA (
∗P < 0.05).
4. Discussion
In the present study, we demonstrated that the preclinical
eﬀectof4-1BBL-expressingcellularvaccinescanbemarkedly
improved by combining vaccination with treatment with
anti-CTLA-4 mAb. The combination vaccine resulted in
sustained tumor degradation in all the mice. Our treatment
regimen holds great promise for a positive clinical eﬀect in
humans.
Actually, cancer occurrence and development has been
demonstrated to be associated with escape from immune
surveillance. The prostate cancer vaccine alone was unable to
cause complete tumor regression, which could reﬂect either
that the initial CD8+ T-cell-mediated antitumor immune
responsesimplyisnotpotentenoughtocompletelyeliminate
all the cancer cells or that the cancer cells have lost
their immunogenicity. There might be several reasons for
that including (1) low-level expression of the major MHC
molecules, (2) absence of recognized tumor Ags, (3) poor
costimulatory molecule expression, or (4) some kind of im-
munosuppressionoftheCD8+ T-cellresponsesuchasTGF-β
[18].4-1BBisaninduciblememberoftheTNFRsuperfamily
that has profound eﬀects on T cells, including activation of
both CD4+ and CD8+ T cells, enhanced expansion [19, 20],
increased long-term survival [21, 22], and antiapoptosis
of activation-induced CD8+ T cells [23]. Costimulation
through 4-1BB can also promote enhanced production of
cytokines such as IL-2, IL-4, and IFN-γ [19, 24]. Regarding
this, we sought to understand the eﬀect on tumor-speciﬁc T
cellresponsesofsimultaneouslyactivelydrivingproliferation
andsurvivalthroughactivationofthecostimulatoryreceptor
4-1BB, while at the same time eliminating a major brake on
expansion via blocking the coinhibitory receptor CTLA-4.
Weeks after tumor cell inoculation
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Figure 5: Kaplan-Meier survival curve of mice. According to the
log-rank test, there were signiﬁcant diﬀerences among ﬁve groups
(P<0.05). Compared with those of the other two groups, the
survival rate of mice immunized with 4-1BBL-expressing cellular
vaccines combined with CTLA-4 blockade was signiﬁcant higher
than those of mice immunized with either alone (P<0.05).
In murine experiments, activation of 4-1BB with 4-
1BB mAb can lead to rejection of many tumours [25].
Indeed, phase I and II clinical trials using anti-4-1BB therapy
for advanced cancers are underway [26]. However, anti-4-
1BB antibodies can cause severe immune system anomalies
when given systemically [27]. Thus, in the present study,
we use 4-1BBL-expressing cellular vaccines for treatment
of prostate cancer. Our data indicate that the 4-1BBL-
expressing cellular vaccine did slow tumor growth when
initiated at the time of tumor implantation and resulted in
regression of tumors in about 2/5 of the mice. Moreover,
the combination of 4-1BBL-expressing cellular vaccine with
CTLA-4 blockade induced rejection of all tumors injected at
the same day. These results suggest that 4-1BBL-expressing
cellular vaccines can be markedly improved by combining
vaccination with treatment with anti-CTLA-4 mAb. In the
study, we demonstrated the number of CD8+ and CD4+ T
cells in RM-1 tumors in mice immunized with anti-CTLA-
4 mAb and 4-1BBL-expressing cellular vaccines (data not
shown), which suggest enhancement of cytotoxicity of TIL
might be a way for the combination of vaccine to execute
antitumor eﬀect. The same results were observed in B16
melanoma by Kocak et al. [28] and Curran et al. [29].
Our results demonstrated that CTL activity of spleno-
cytes and cytokine from mice immunized with 4-1BBL-
expressing cellular vaccines and CTLA-4 blockade was
dramaticallyincreasedcomparedwiththatfrommiceimmu-
nized with either alone. Vaccination with parental RM-1,Clinical and Developmental Immunology 5
RM-1/pCDNA3.1, and control hamster IgG had no eﬀect on
CTLactivity.ThemaineﬀectorcellsperformingCTLactivity
are CD8+ T cells, while the main cells producing cytokines
suchasIL-2,IFN-γ,andTNF -αareCD4+ Th1cells.Th1cells
play a critical role in cellular immunity by their cytokines
activating CD8+ T cells. Long-term survival of mice immu-
nized with 4-1BBL-expressing cellular vaccines and CTLA-
4 blockade when rechallenged lethal dose of parental
RM-1 cells indicated that the combination of vaccines
executes antitumor immune response by activating CD8+
and CD4+ T cells.
The ﬁndings presented in this study have signiﬁcant
implications for immunotherapy in humans. Our results
suggested that it is important to consider whether two
treatments will act synergistically when developing an
immunotherapeutic strategy. Moreover, they also suggest
that CTLA-4 blockade may be a vital adjuvant for a 4-1BBL-
expressing vaccine used to treat cancers.
5. Conclusion
In summary, we concluded that the combination of activa-
tion of 4-1BB and blockade of CTLA-4 has a higher potential
antitumor eﬀect and may oﬀer a new strategy for prostate
cancer immunotherapy.
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